GB2407501A - Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell - Google Patents

Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell Download PDF

Info

Publication number
GB2407501A
GB2407501A GB0325625A GB0325625A GB2407501A GB 2407501 A GB2407501 A GB 2407501A GB 0325625 A GB0325625 A GB 0325625A GB 0325625 A GB0325625 A GB 0325625A GB 2407501 A GB2407501 A GB 2407501A
Authority
GB
United Kingdom
Prior art keywords
nanoparticles
antigen
nanoparticles according
polymer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0325625A
Other languages
English (en)
Other versions
GB0325625D0 (en
Inventor
Barbara Ensoli
Antonella Caputo
Michelle Laus
Luisa Tondelli
Katia Sparnacci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanità
Original Assignee
Istituto Superiore di Sanità
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanità filed Critical Istituto Superiore di Sanità
Priority to GB0325625A priority Critical patent/GB2407501A/en
Publication of GB0325625D0 publication Critical patent/GB0325625D0/en
Priority to JP2006537242A priority patent/JP2007509902A/ja
Priority to US10/577,973 priority patent/US20060280798A1/en
Priority to EP04797557A priority patent/EP1701711A1/en
Priority to PCT/EP2004/012420 priority patent/WO2005048997A1/en
Publication of GB2407501A publication Critical patent/GB2407501A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0325625A 2003-11-03 2003-11-03 Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell Withdrawn GB2407501A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB0325625A GB2407501A (en) 2003-11-03 2003-11-03 Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
JP2006537242A JP2007509902A (ja) 2003-11-03 2004-11-03 薬理学的に活性のある薬剤の送達のためのナノ粒子
US10/577,973 US20060280798A1 (en) 2003-11-03 2004-11-03 Nanoparticles for delivery of a pharmacologically active agent
EP04797557A EP1701711A1 (en) 2003-11-03 2004-11-03 Nanoparticles for delivery of a pharmacologically active agent
PCT/EP2004/012420 WO2005048997A1 (en) 2003-11-03 2004-11-03 Nanoparticles for delivery of a pharmacologically active agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0325625A GB2407501A (en) 2003-11-03 2003-11-03 Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell

Publications (2)

Publication Number Publication Date
GB0325625D0 GB0325625D0 (en) 2003-12-10
GB2407501A true GB2407501A (en) 2005-05-04

Family

ID=29725850

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0325625A Withdrawn GB2407501A (en) 2003-11-03 2003-11-03 Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell

Country Status (5)

Country Link
US (1) US20060280798A1 (enExample)
EP (1) EP1701711A1 (enExample)
JP (1) JP2007509902A (enExample)
GB (1) GB2407501A (enExample)
WO (1) WO2005048997A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909094A1 (fr) * 2006-11-28 2008-05-30 Arkema France Memoire optique 3d comprenant des particules multicouches comprenant un monomere photoactif porteur d'un groupement photoisomerisable.
WO2009056344A1 (en) * 2007-11-02 2009-05-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Core-shell macromolecules for specific cell nucleus or/and cell matrix staining
EP2044150A4 (en) * 2006-07-21 2010-09-01 Nektar Therapeutics POLYMER REAGENTS WITH A VINYL END GROUP AND CONJUGATES MADE THEREFROM

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877250B2 (en) 2005-12-20 2014-11-04 Bridgestone Corporation Hollow nano-particles and method thereof
EP2029119A2 (de) * 2006-06-08 2009-03-04 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste polymernanopartikel für diagnostische und therapeutische anwendungen
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
WO2010078320A2 (en) * 2008-12-31 2010-07-08 Bridgestone Corporation Core-first nanoparticle formation process, nanoparticle, and composition
JP5317105B2 (ja) * 2009-01-13 2013-10-16 国立大学法人 筑波大学 四級化アミノ基を有する架橋ポリマー由来のポリマー微粒子と核酸の複合体
US9062144B2 (en) 2009-04-03 2015-06-23 Bridgestone Corporation Hairy polymeric nanoparticles with first and second shell block polymer arms
US11285494B2 (en) 2009-08-25 2022-03-29 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
US10751464B2 (en) 2009-08-25 2020-08-25 Nanoshell Company, Llc Therapeutic retrieval of targets in biological fluids
CN102625710A (zh) 2009-08-25 2012-08-01 艾格尼丝·奥斯塔芬 携氧的抗湍流的高密度亚微米颗粒的合成
US10099227B2 (en) 2009-08-25 2018-10-16 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
IT1397011B1 (it) * 2009-10-14 2012-12-20 Univ Ferrara Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
US9115222B2 (en) 2009-12-29 2015-08-25 Bridgestone Corporation Well defined, highly crosslinked nanoparticles and method for making same
KR20130100290A (ko) 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
EP2720682B1 (en) * 2011-06-17 2016-11-23 Evonik Röhm GmbH Coating composition suitable for pharmaceutical or nutraceutical dosage forms
US9428604B1 (en) 2011-12-30 2016-08-30 Bridgestone Corporation Nanoparticle fillers and methods of mixing into elastomers
WO2015026947A1 (en) * 2013-08-21 2015-02-26 The Regents Of The University Of California Composition and methods for culturing cells
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
CN110808137B (zh) * 2019-11-13 2021-08-17 山东师范大学 一种磁性富集材料、水体细菌检测试剂盒及应用
EP4221685A1 (en) 2020-09-29 2023-08-09 Oxford University Innovation Limited Stroke treatment
WO2022109274A1 (en) * 2020-11-20 2022-05-27 Nouryon Chemicals International B.V. Fluorescent polymers and solutions thereof for scale control in aqueous systems
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US12618094B2 (en) * 2022-01-05 2026-05-05 City University Of Hong Kong Core-shell nanoparticles, methods of producing the same, and uses thereof for detecting extracellular polymeric substances
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
WO2026024279A1 (en) * 2024-07-24 2026-01-29 Kemira Oyj Surfactant compositions derived from waste streams, and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183658B1 (en) * 1996-04-10 2001-02-06 Institut Für Neue Materialien Gem. Gmbh Process for preparing agglomerate-free nanoscalar iron oxide particles with a hydrolysis resistant coating
WO2003064557A1 (de) * 2002-01-31 2003-08-07 Forschungszentrum Karlsruhe Gmbh Fluoreszierende nanoteilchen und deren herstellung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723218A (en) * 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
DE19746362A1 (de) * 1996-10-23 1998-04-30 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von biologisch aktiven Polymernanopartikel-Nucleinsäure-Konjugaten
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
DE60000677T2 (de) * 1999-01-12 2003-07-03 Quanam Medical Corp., Santa Clara Polymerzusammensetzung für intraluminalen stent
US6974706B1 (en) * 2003-01-16 2005-12-13 University Of Florida Research Foundation, Inc. Application of biosensors for diagnosis and treatment of disease
US6315405B1 (en) * 2000-03-27 2001-11-13 Eastman Kodak Company Ink jet printing method
WO2002000191A2 (de) * 2000-06-29 2002-01-03 Bernina Biosystems Gmbh Bdellosomen
DE10118852A1 (de) * 2001-04-17 2002-10-31 Fricker Gert Bdellosomen
AU2002226955B2 (en) * 2001-11-23 2006-04-27 Allergan Pharmaceuticals International Limited Pharmaceutical dosage form with multiple coatings
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183658B1 (en) * 1996-04-10 2001-02-06 Institut Für Neue Materialien Gem. Gmbh Process for preparing agglomerate-free nanoscalar iron oxide particles with a hydrolysis resistant coating
WO2003064557A1 (de) * 2002-01-31 2003-08-07 Forschungszentrum Karlsruhe Gmbh Fluoreszierende nanoteilchen und deren herstellung

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044150A4 (en) * 2006-07-21 2010-09-01 Nektar Therapeutics POLYMER REAGENTS WITH A VINYL END GROUP AND CONJUGATES MADE THEREFROM
US8268948B2 (en) 2006-07-21 2012-09-18 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
US8905235B2 (en) 2006-07-21 2014-12-09 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
FR2909094A1 (fr) * 2006-11-28 2008-05-30 Arkema France Memoire optique 3d comprenant des particules multicouches comprenant un monomere photoactif porteur d'un groupement photoisomerisable.
WO2008065299A1 (fr) * 2006-11-28 2008-06-05 Arkema France Memoire optique 3d comprenant des particules multicouches comprenant un monomere photoactif porteur d'un groupement photoisomerisable
WO2009056344A1 (en) * 2007-11-02 2009-05-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Core-shell macromolecules for specific cell nucleus or/and cell matrix staining

Also Published As

Publication number Publication date
JP2007509902A (ja) 2007-04-19
WO2005048997A1 (en) 2005-06-02
US20060280798A1 (en) 2006-12-14
EP1701711A1 (en) 2006-09-20
GB0325625D0 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
US20060280798A1 (en) Nanoparticles for delivery of a pharmacologically active agent
CN1230152C (zh) 水凝胶颗粒制剂
Xiang et al. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles
US20180071387A1 (en) Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20100173005A1 (en) Microparticle formulations for sustained-release of bioactive compounds
Castaldello et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination
Voltan et al. Preparation and characterization of innovative protein-coated poly (methylmethacrylate) core-shell nanoparticles for vaccine purposes
US20100272805A1 (en) Hydrogels for combinatorial delivery of immune-modulating biomolecules
JP2004502721A (ja) Ｄｎａワクチン送達のためのミクロスフェアおよびアジュバント
Liu et al. A simple self-adjuvanting biomimetic nanovaccine self-assembled with the conjugate of phospholipids and nucleotides can induce a strong cancer immunotherapeutic effect
GB2407500A (en) Use of microparticles for antigen delivery
AU2931200A (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
US20020051821A1 (en) Aliginate particle formulation
US20050191361A1 (en) Hydrogel particle formation
CN113786481A (zh) 一种抗肿瘤疫苗及其制备方法
Slomkowski et al. Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery
White et al. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants
US20220370488A1 (en) Mucus penetrating particle compositions and methods of use thereof enhancing immune response
Dong et al. Nano-delivery vehicles/adjuvants for DNA vaccination against HIV
JPWO2004092388A1 (ja) ベクター
Kasturi Design, synthesis, and evaluation of synthetic particulate delivery systems in DNA and protein vaccine delivery
Kreuter + 25 nm. Alternatively, empty nanoparticles

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)